{"name":"Edwin Posadas, MD","slug":"edwin-posadas-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2029-03-01","label":"Tazverik Phase 3 readout (Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma)","drug":"Tazverik","drugSlug":"tazverik","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tazverik","genericName":"Tazverik","slug":"tazverik","indication":"Epithelioid sarcoma","status":"discontinued"}]}],"pipeline":[{"name":"Tazverik","genericName":"Tazverik","slug":"tazverik","phase":"discontinued","mechanism":"Polycomb protein EED, Histone-lysine N-methyltransferase EZH1, Histone-lysine N-methyltransferase EZH2","indications":["Epithelioid sarcoma","Follicular lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxORFFHakhxb0lEaUk5N1ZoV0QtLTRsZDlPNnJ3M2hucXVzWHkzMC11TENfWE9zTTltWG5fSndpU2tjOW5UVjNlTjZObWxVYVBLSmdWNDZtU2xIdkJLdlRWeGFjcmR1RW9wUm9oR1RZQW82eVYwejJzMVptZmRyQVlTUDIwOFVRYzdaQnNfUExGNlBKb1FXdksxeWROMnB6dTB0MTlmUnlVZXpLRnlBamgxY2UyZkVOYjBPTmtsTENCTFBrOGNzSU52WXZnU1h4aUdI?oc=5","date":"2025-02-14","type":"pipeline","source":"Oncology News Central","summary":"Talazoparib (Talzenna) Plus Enzalutamide (Xtandi) Improves Survival in Prostate Cancer - Oncology News Central","headline":"Talazoparib (Talzenna) Plus Enzalutamide (Xtandi) Improves Survival in Prostate Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOYXo0NlRuRm5UdGRwbTJJdmR5WmV6dHNmOURhYk9HMm4tYlU2LXlnbGpXVnhaUFF1QjVuRUR2U2dnenliU0M5YURYWmVwVWNob2hDdGJXcV9nTTg4aURSWlp2VVBMYUNCOGFRNXFBTzJXM05pSExiSS1XQUpGUFM0ejhXQU9nc2YzZFFacWhsbWNGdGswd25DYkt2LWZWY0lSOEVoc01ab2dvMHNBXzRrVmJ2Z3k2clU3NFJtTUdEVDZTYW9HdEc3UjdR?oc=5","date":"2025-02-10","type":"pipeline","source":"Oncology News Central","summary":"ADC Advances, Potential Practice-Changing Research on Tap for ASCO GU 2025 - Oncology News Central","headline":"ADC Advances, Potential Practice-Changing Research on Tap for ASCO GU 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxOdlI3eVB0M0xfNDdYN1ZMT0ticU1zSEpQVjVmX1pPWkRSYy16TkJZdlVXd2FmcEpOOWE1OHBNSm53UFAtQXM3N3FPaTdxczRZcW5DbUdUVFZKQkswc2VROW9rNU1qM2l6OWpOUU13cDNYczRmRGI4b2ZXME9HRi1KcmtmNUlNSkY5cFA0NGZOdnpReUR6NWNxc09LMGtjVHZneW9faDhoX0h3WXFfLWtHend1UVkzY2EySTNTSUx1WQ?oc=5","date":"2025-02-07","type":"earnings","source":"Oncology News Central","summary":"Public Dollars, Private Profits? Cancer Drug’s Cost Sky High Despite Taxpayer Funding - Oncology News Central","headline":"Public Dollars, Private Profits? Cancer Drug’s Cost Sky High Despite Taxpayer Funding","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE1QamNFREhJbkJjVnhacEItY1R2MndiaDZvWlZMOVJFZFQ0VEoxMU13X2RrTW1IS3h4bXFOMVY5ZFp1ZVptN3lPM09nQ2Q4VDdPOWtEandUTU40T1NZbjlVaU1VRFNNbWNpZnBleE1qMHVuS1pa?oc=5","date":"2024-03-26","type":"pipeline","source":"Wiley","summary":"A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer - Wiley","headline":"A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with pr","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}